

UDK 37

ISSN 2545 - 4439
ISSN 1857 - 923X

INTERNATIONAL JOURNAL

Institute of Knowledge Management

KNOWLEDGE



Scientific Papers

Vol. 46. 4.

MEDICAL SCIENCES AND HEALTH



KIJ

Vol. 46

No. 4

pp. 475 - 708

Skopje 2021

KNOWLEDGE



INTERNATIONAL JOURNAL

**SCIENTIFIC PAPERS
VOL. 46.4**

June, 2021

**INSTITUTE OF KNOWLEDGE MANAGEMENT
SKOPJE**



KNOWLEDGE
International Journal Scientific Papers Vol. 46.4

ADVISORY BOARD

Vlado Kambovski PhD, Robert Dimitrovski PhD, Siniša Zarić PhD, Maria Kavdanska PhD, Venelin Terziev PhD, Mirjana Borota – Popovska PhD, Veselin Videv PhD, Ivo Zupanovic, PhD, Savo Ashtalkoski PhD, Zivota Radosavljević PhD, Laste Spasovski PhD, Mersad Mujevic PhD, Milka Zdravkovska PhD, Drago Cvijanovic PhD, Predrag Trajković PhD, Lazar Stosic PhD, Krasimira Staneva PhD, Nebojsa Pavlović PhD, Daniela Todorova PhD, Baki Koleci PhD, Lisen Bashkurti PhD, Zoran Srzentić PhD, Sinisa Opic PhD, Marija Kostic PhD

Print: GRAFOPROM – Bitola

Editor: IKM – Skopje

Editor in chief

Robert Dimitrovski, PhD

KNOWLEDGE - International Journal Scientific Papers Vol. 46.4

ISSN 1857-923X (for e-version)

ISSN 2545 – 4439 (for printed version)

INTERNATIONAL EDITORIAL BOARD

President: Academic, Prof. Vlado Kambovski PhD, Skopje (N. Macedonia)

Vice presidents:

Prof. Robert Dimitrovski PhD, Institute of Knowledge Management, Skopje (N. Macedonia)

Prof. Sinisa Zaric, PhD, Faculty of Economics, University of Belgrade, Belgrade (Serbia)

Prof. Venelin Terziev PhD, University of Rousse, Rousse (Bulgaria)

Prof. Mersad Mujevic PhD, Public Procurement Administration of Montenegro (Montenegro)

Prof. Tihomir Domazet PhD, President of the Croatian Institute for Finance and Accounting, Zagreb (Croatia)

Members:

- Prof. Azra Adjajlic – Dedovic PhD, Faculty of criminology and security, Sarajevo (Bosnia & Herzegovina)
- Prof. Aleksandar Korablev PhD, Faculty of economy and management, Saint Petersburg State Forest Technical University, Saint Petersburg (Russian Federation)
- Prof. Anita Trajkovska PhD, Rochester University (USA)
- Prof. Aziz Pollozhani PhD, Rector, University Mother Teresa, Skopje (N.Macedonia)
- Prof. Anka Trajkovska-Petkoska PhD, UKLO, Faculty of technology and technical sciences, Bitola (N. Macedonia)
- Prof. Aneta Mijoska PhD, Faculty of Dentistry, University “St. Cyril and Methodius”, Skopje (N. Macedonia)
- Prof. Alisabri Sabani PhD, Faculty of criminology and security, Sarajevo (Bosnia & Herzegovina)
- Prof. Artan Nimani PhD, Rector, University of Gjakova “Fehmi Agani” (Kosovo)
- Prof. Ahmad Zakeri PhD, University of Wolverhampton, (United Kingdom)
- Prof. Ana Dzumalieva PhD, South-West University “Neofit Rilski”, Blagoevgrad (Bulgaria)
- Prof. Ali Hajro, PhD, Military Academy “Mihailo Apostolski”, Skopje (N. Macedonia)
- Prof. Branko Sotirov PhD, University of Rousse, Rousse (Bulgaria)
- Prof. Branko Boshkovic, PhD, College of Sports and Health, Belgrade (Serbia)
- Prof. Branimir Kampl PhD, Institute SANO, Zagreb (Croatia)
- Prof. Baki Koleci PhD, University Hadzi Zeka, Peja (Kosovo)
- Prof. Branislav Simonovic PhD, Faculty of Law, Kragujevac (Serbia)
- Prof. Bistra Angelovska, Faculty of Medicine, University “Goce Delcev”, Shtip (N.Macedonia)
- Prof. Cezar Birzea, PhD, National School for Political and Administrative Studies, Bucharest (Romania)
- Prof. Cvetko Andreevski, Faculty of Tourism, UKLO, Bitola (N.Macedonia)
- Prof. Drago Cvijanovic, PhD, Faculty of Hotel Management and Tourism, University of Kragujevac, Vrnjacka Banja (Serbia)
- Prof. Dusan Ristic, PhD Emeritus, College of professional studies in Management and Business Communication, Novi Sad (Serbia)
- Prof. Darijo Jerkovic PhD, Faculty of Business Economy, University “Vitez”, (Bosnia & Herzegovina)
- Prof. Daniela Todorova PhD, “Todor Kableshev” University of Transport, Sofia (Bulgaria)
- Prof. Dragan Kokovic PhD, University of Novi Sad, Novi Sad (Serbia)
- Prof. Dragan Marinkovic PhD, High health – sanitary school for professional studies, Belgrade (Serbia)

- Prof. Daniela Ivanova Popova PhD, Faculty of Public Health and Sport, SWU Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Dzulijana Tomovska, PhD, Faculty of Biotechnical sciences, Bitola (N.Macedonia)
- Prof. Evgenia Penkova-Pantaleeva PhD, UNWE -Sofia (Bulgaria)
- Prof. Fadil Millaku, PhD, University “Hadzi Zeka”, Peja (Kosovo)
- Prof. Fatos Ukaj, University “Hasan Prishtina”, Prishtina (Kosovo)
- Prof. Georgi Georgiev PhD, National Military University “Vasil Levski”, Veliko Trnovo (Bulgaria)
- Prof. Halit Shabani, PhD, University “Hadzi Zeka”, Peja (Kosovo)
- Prof. Halima Sofradzija, PhD, University of Sarajevo, Sarajevo (Bosnia and Herzegovina)
- Prof. Haris Halilovic, Faculty of criminology and security, University of Sarajevo, Sarajevo (Bosnia and Herzegovina)
- Prof. Helmut Shramke PhD, former Head of the University of Vienna Reform Group (Austria)
- Prof. Hristina Georgieva Yancheva, PhD, Agricultural University, Plovdiv (Bulgaria)
- Prof. Hristo Beloev PhD, Bulgarian Academy of Science, Rector of the University of Rousse (Bulgaria)
- Prof. Hristina Milcheva, Medical college, Trakia University, Stara Zagora (Bulgaria)
- Prof. Izet Zeqiri, PhD, Academic, SEEU, Tetovo (N.Macedonia)
- Prof. Ivan Marchevski, PhD, D.A. Tsenov Academy of Economics, Svishtov (Bulgaria)
- Prof. Ibrahim Obhodjas PhD, Faculty of Business Economy, University “Vitez”, (Bosnia & Herzegovina)
- Doc. Igor Stubelj, PhD, PhD, Faculty of Management, Primorska University, Koper (Slovenia)
- Prof. Ivo Zupanovic, PhD, Faculty of Business and Tourism, Budva (Montenegro)
- Prof. Ivan Blazhevski, PhD, Institute for Sociological, Political and Juridical Research, Skopje (N.Macedonia)
- Prof. Isa Spahiu PhD, AAB University, Prishtina (Kosovo)
- Prof. Ivana Jelik PhD, University of Podgorica, Faculty of Law, Podgorica (Montenegro)
- Prof. Islam Hasani PhD, Kingston University (Bahrein)
- Prof. Jamila Jaganjac PhD, Faculty of Business Economy, University “Vitez”, (Bosnia & Herzegovina)
- Prof. Jova Ateljevic PhD, Faculty of Economy, University of Banja Luka, (Bosnia & Herzegovina)
- Prof. Jonko Kunchev PhD, University „Cernorizec Hrabar“ - Varna (Bulgaria)
- Prof Karl Schopf, PhD, Akademie fur wissenschaftliche forchung und studium, Wien (Austria)
- Prof. Katerina Belichovska, PhD, Faculty of Agricultural Sciences, UKIM, Skopje (N. Macedonia)
- Prof. Krasimir Petkov, PhD, National Sports Academy “Vassil Levski”, Sofia (Bulgaria)
- Prof. Kamal Al-Nakib PhD, College of Business Administration Department, Kingdom University (Bahrain)
- Prof. Kiril Lisichkov, Faculty of Technology and Metallurgy, UKIM, Skopje (N.Macedonia)
- Prof. Krasimira Staneva PhD, University of Forestry, Sofia (Bulgaria)
- Prof. Lidija Tozi PhD, Faculty of Pharmacy, Ss. Cyril and Methodius University, Skopje (N.Macedonia)
- Prof. Laste Spasovski PhD, Vocational and educational centre, Skopje (N.Macedonia)
- Prof. Larisa Velic, PhD, Faculty of Law, University of Zenica, Zenica (Bosnia and Herzegovina)
- Prof. Łukasz Tomczyk PhD, Pedagogical University of Cracow (Poland)

- Prof. Lujza Grueva, PhD, Faculty of Medical Sciences, UKIM, Skopje (N.Macedonia)
- Prof. Lazar Stosic, PhD, Association for development of science, engineering and education, Vranje (Serbia)
- Prof. Lulzim Zeneli PhD, University of Gjakova “Fehmi Agani” (Kosovo)
- Prof. Lisen Bashkurti PhD, Global Vice President of Sun Moon University (Albania)
- Prof. Lence Mircevska PhD, High Medicine School, Bitola, (N.Macedonia)
- Prof. Ljupce Kocovski PhD, Faculty of Biotechnical sciences, Bitola (N.Macedonia)
- Prof. Marusya Lyubcheva PhD, University “Prof. Asen Zlatarov”, Member of the European Parliament, Burgas (Bulgaria)
- Prof. Marija Magdinceva – Shopova PhD, Faculty of tourism and business logistics, University “Goce Delchev”, Shtip (N. Macedonia)
- Prof. Maria Kavdanska PhD, Faculty of Pedagogy, South-West University Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Maja Lubenova Cholakova PhD, Faculty of Public Health and Sport, SWU Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Mirjana Borota-Popovska, PhD, Centre for Management and Human Resource Development, Institute for Sociological, Political and Juridical Research, Skopje (N.Macedonia)
- Prof. Mihail Garevski, PhD, Institute of Earthquake Engineering and Engineering Seismology, Skopje (N.Macedonia)
- Prof. Misho Hristovski PhD, Faculty of Veterinary Medicine, Ss. Cyril and Methodius University, Skopje (N.Macedonia)
- Prof. Mitko Kotovchevski, PhD, Faculty of Philosophy, UKIM, Skopje (N.Macedonia)
- Prof. Milan Radosavljevic PhD, Dean, Faculty of strategic and operational management, Union University, Belgrade (Serbia)
- Prof. Marija Topuzovska-Latkovikj, PhD, Centre for Management and Human Resource Development, Institute for Sociological, Political and Juridical Research, Skopje (N.Macedonia)
- Prof. Marija Knezevic PhD, Academic, Banja Luka, (Bosnia and Herzegovina)
- Prof. Margarita Bogdanova PhD, D.A.Tsenov Academy of Economics, Svishtov (Bulgaria)
- Prof. Mahmut Chelik PhD, Faculty of Philology, University “Goce Delchev”, Shtip (N.Macedonia)
- Prof. Mihajlo Petrovski, PhD, Faculty of Medical Sciences, University “Goce Delchev”, Shtip (N.Macedonia)
- Prof. Marija Mandaric PhD, Faculty of Hotel Management and Tourism, University of Kragujevac, Vrnjacka Banja (Serbia)
- Prof. Marina Simin PhD, College of professional studies in Management and Business Communication, Sremski Karlovci (Serbia)
- Prof. Miladin Kalinic, College of professional studies in Management and Business Communication, Sremski Karlovci (Serbia)
- Prof. Marijan Tanushevski PhD, Macedonian Scientific Society, Bitola (N. Macedonia)
- Prof. Mitre Stojanovski PhD, Faculty of Biotechnical sciences, Bitola (N.Macedonia)
- Prof. Miodrag Smelcerovic PhD, High Technological and Artistic Vocational School, Leskovac (Serbia)
- Prof. Nadka Kostadinova, Faculty of Economics, Trakia University, Stara Zagora (Bulgaria)
- Prof. Natalija Kirejenko PhD, Faculty For economic and Business, Institute of Entrepreneurial Activity, Minsk (Belarus)
- Prof. Nenad Taneski PhD, Military Academy “Mihailo Apostolski”, Skopje (N.Macedonia)
- Prof. Nevenka Tatkovic PhD, Juraj Dobrila University of Pula, Pula (Croatia)
- Prof. Nedžad Korajlic PhD, Faculty of criminal justice and security, University of Sarajevo (Bosnia and Herzegovina)

- Prof. Nikola Sabev, PhD, Angel Kanchev University of Ruse, Ruse (Bulgaria)
- Prof. Nonka Mateva PhD, Medical University, Plovdiv (Bulgaria)
- Prof. Nikolay Georgiev PhD, “Todor Kableshkov” University of Transport, Sofia (Bulgaria)
- Prof. Nishad M. Navaz PhD, Kingdom University (India)
- Prof. Nano Ruzhin PhD, Faculty of Law, AUE-FON University, Skopje (N.Macedonia)
- Prof. Oliver Dimitrijevic PhD, High medicine school for professional studies “Hipokrat”, Bujanovac (Serbia)
- Prof. Paul Sergius Koku, PhD, Florida State University, Florida (USA)
- Prof. Primoz Dolenc, PhD, Faculty of Management, Primorska University, Koper (Slovenia)
- Prof. Petar Kolev PhD, “Todor Kableshkov” University of Transport, Sofia (Bulgaria)
- Prof. Pere Tumbas PhD, Faculty of Economics, University of Novi Sad, Subotica (Serbia)
- Prof. Rade Ratkovic PhD, Faculty of Business and Tourism, Budva (Montenegro)
- Prof. Rositsa Chobanova PhD, University of Telecommunications and Posts, Sofia (Bulgaria)
- Prof. Rossana Piccolo PhD, Università degli studi della Campania - Luigi Vanvitelli (Italy)
- Prof. Rumen Valcovski PhD, Imunolab Sofia (Bulgaria)
- Prof. Rumen Stefanov PhD, Faculty of public health, Medical University of Plovdiv (Bulgaria)
- Prof. Rumen Tomov PhD, University of Forestry, Sofia (Bulgaria)
- Prof. Sasho Korunoski PhD, UKLO, Bitola (N.Macedonia)
- Prof. Snezhana Lazarevic, PhD, College of Sports and Health, Belgrade (Serbia)
- Prof. Stojan Ivanov Ivanov PhD, Faculty of Public Health and Sport, SWU Neofit Rilski, Blagoevgrad (Bulgaria)
- Prof. Stojna Ristevska PhD, High Medicine School, Bitola, (N. Macedonia)
- Prof. Suzana Pavlovic PhD, High health – sanitary school for professional studies, Belgrade (Serbia)
- Prof. Sandra Zivanovic, PhD, Faculty of Hotel Management and Tourism, University of Kragujevac, Vrnjacka Banja (Serbia)
- Prof. Shyqeri Kabashi, College “Biznesi”, Prishtina (Kosovo)
- Prof. Temelko Risteski PhD, Faculty of Law, AUE-FON University, Skopje (N. Macedonia)
- Prof. Todor Krystevich, D.A. Tsenov Academy of Economics, Svishtov (Bulgaria)
- Prof. Todorcka Atanasova, Faculty of Economics, Trakia University, Stara Zagora (Bulgaria)
- Prof. Tzako Pantaleev PhD, NBUniversity, Sofia (Bulgaria)
- Prof. Vojislav Babic PhD, Institute of Sociology, University of Belgrade (Serbia)
- Prof. Volodymyr Denysyuk, PhD, Dobrov Center for Scientific and Technological Potential and History studies at the National Academy of Sciences of Ukraine (Ukraine)
- Prof. Valentina Staneva PhD, “Todor Kableshkov” University of Transport, Sofia (Bulgaria)
- Prof. Venus Del Rosario PhD, Arab Open University (Philippines)
- Prof. Vjollca Dibra PhD, University of Gjakova “Fehmi Agani” (Kosovo)
- Prof. Yuri Doroshenko PhD, Dean, Faculty of Economics and Management, Belgorod (Russian Federation)
- Prof. Zlatko Pejkovski, PhD, Faculty of Agricultural Sciences, UKIM, Skopje (N.Macedonia)
- Prof. Zivota Radosavljevic PhD, Faculty FORCUP, Union University, Belgrade (Serbia)
- Prof. Zorka Jugovic PhD, High health – sanitary school for professional studies, Belgrade (Serbia)

REVIEW PROCEDURE AND REVIEW BOARD

Each paper is reviewed by the editor and, if it is judged suitable for this publication, it is then sent to two referees for double blind peer review.

The editorial review board is consisted of 63 members, full professors in the fields 1) Natural and mathematical sciences, 2) Technical and technological sciences, 3) Medical sciences and Health, 4) Biotechnical sciences, 5) Social sciences, and 6) Humanities from all the Balkan countries and the region.

CONTENTS

CORRELATION OF PREOPERATIVE SERUM MARKERS WITH THE GRADE OF COMPLICATED APPENDICITIS	491
Andrej Nikolovski	491
Aleksandar Otljanski	491
Rexhep Selmani	491
Svetozar Antovic	491
Nikola Jankulovski	491
PERFORATED SOLITARY CECAL DIVERTICULITIS CAUSING ACUTE ABDOMEN: A REPORT OF 2 CASES – CASE REPORT.....	495
Radomir Gelevski	495
Gjorgji Jota	495
Gjorgji Trajkovski	495
Bojan Trencic	495
Berat Dalipi	495
Aneta Gjorgjievska	495
MEDICAL ERRORS IN OBSTETRICS AND GYNECOLOGY IN BULGARIA – A SURVEY OF THE JUDICIAL PRACTICE	499
Ivan Kostov	499
Gergana Ingilizova	499
Sergei Slavov	499
THE ROLE OF DEHYDROEPIANDROSTERONE SULPHATE AND TESTOSTERONE IN ERECTILE DYSFUNCTION IN PATIENTS TREATED WITH 5 ALPHA REDUCTASE INHIBITORS	505
Maja Sofronievska Glavinov	505
THE RELIABILITY OF THE ANALYTICAL METHODS FOR DETERMINATION OF CONJUGATED ANTIBODIES AFTER FINAL PREPARATION IN SERUM SAMPLES OF RAT ..	511
Zana Rustemi	511
David Mwanza Wanjeh	511
Paulina Apostolova.....	511
Aschalew Alemu Marie.....	511
Icko Gjorgoski	511
Emilija Janevik-Ivanovska	511
COMPLICATIONS IN THE TREATMENT OF A LOWER JAW FRACTURE WITH STANDARD STRAPS BY THE VASILEV METHOD	521
Rosen Tsolov	521
Georgi Yordanov	521
SEGMENTAL UTILITY ARCH TECHNIQUE AS RATIONAL APPROACH IN SPECIFIC ORTHODONTIC CASES-CANINE RETRACTION-case report.....	525
Vesna Trpevska	525
Ivan Tanatarec	525
DENTAL CARIES AMONG INSTITUTIONALIZED ELDERLY	531
Mihajlo Petrovski	531
Kiro Papakoca.....	531
Sofija Carceva-Salja	531
Olivera Terzieva-Petrovska	531
FIRST IMPRESSIONS BASED ON SMILE DESIGN CUSTOMIZATION.....	537
Georgi Iliev.....	537

TREATMENT OF COMPLICATED SAGITTAL FRACTURE OF THE LOWER JAW WITH WIRE OSTEOSYNTHESIS	543
Rosen Tsolov	543
Georgi Yordanov	543
INFLUENCE OF DIFFERENT PERIODONTAL THERAPEUTIC PROTOCOLS ON CEMENTUM THICKNESS.....	547
Mihajlo Petrovski	547
Ana Minovska.....	547
RESEARCH OF OCCLUSAL RELATIONS IN THE FINAL PHASE OF ORTHODONTIC TREATMENT AND IN THE RETENTION PHASE.....	555
Vesna Trpevska	555
NEED OF ASSISTENCE FOR MAINTAINNING OF ORAL HYGIENE AMONG INSTITUTIONALIZED ELDERLY	561
Mihajlo Petrovski	561
Valentina Simonovska	561
Olivera Terzieva-Petrovska	561
ANATOMICAL VARIATIONS OF THE HELIX AND EARLOBE OF THE HUMAN EAR IN YOUNG POPULATION	567
Svetlana Jovevska.....	567
DIAGNOSTIC ALGORITHM FOR MUSCOLOSKETAL AND ALLERGIC DISEASES WITH OCCUPATIONAL ETIOLOGY	571
Nikoleta Dimitrova	571
Svetlan Dermendjiev	571
Mariela Geneva-Popova	571
CARE, TREATMENT AND EDUCATION OF PATIENTS BEFORE AND AFTER SURGERY	577
Emilija Chapevska.....	577
Gordana Panova.....	577
ALLERGIC CONJUNCTIVITIS	581
Sheribane Emini	581
Strahil Gazepov	581
AMBLYOPIA AND STRABISMUS IN CHILDHOOD	587
Strahil Gazepov	587
Violeta Dziridova.....	587
PREVALENCE OF PATIENTS ON INSULIN THERAPY IN THE MUNICIPALITY OF STIP IN THE PERIOD FROM 2016-2019	597
Verica Andova.....	597
Gordana Panova.....	597
THE HEALTH CONDITION AND THE HEALTH PROTECTION OF THE POPULATION FROM THE SKOPJE REGION FOR 2018.....	603
Valentina Simonovska	603
Vesna Spirova.....	603
STUDY OF THE FREQUENCY OF OBESITY AMONG STUDENTS FROM MEDICAL COLLEGE STARA ZAGORA AND AN ALGORITHM FOR PREVENTION AND TREATMENT	609
Steliana Valeva	609
Nazife Bekir.....	609
THE ROLE OF THE PATRONAGE NURSE IN EDUCATION OF ADOLESCENTS AND YOUNG PEOPLE WHEN VISITING THE SETTLEMENT IN THE MUNICIPALITY OF NEGOTINO	615
Frosina Angelkova.....	615
Gordana Panova.....	615

NEW LIFE FOR OLD MOLECULES	619
Daniel Argilashki.....	619
Bozhidarka Hadzhieva.....	619
Nina Koleva.....	619
Anna Mihaylova	619
CELLULITE AS A MEDICAL PROBLEM AND ITS PLACE IN THE TRAINING OF STUDENTS FROM THE SPECIALTIES "REHABILITATOR THERAPIST" AND "MEDICAL COSMETICIAN"	625
Katya Mollova	625
Anushka Uzunova.....	625
PHYSIOTHERAPY AND ORTHOTIC TREATMENT OF PES CAVUS	631
Kristian Stoychev	631
CHRONIC URTICARIA.....	633
Vaska Spaskova.....	633
METHODOLOGY OF INTENSIVE CARE IN BURNS	639
Anushka Dimitrova.....	639
STUDY AND ANALYSIS OF THE DEGREE OF DISABILITY IN VARIOUS TRAUMATIC AGENTS.....	645
Nadia Manolova	645
Kristin Nacheva	645
CONDITIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SKOPJE REGION POPULATION FROM 2014-2018.....	649
Valentina Simonovska	649
Milka Zdravkovska.....	649
CARE, TREATMENT AND EDUCATION IN CHILDREN WITH SPECIAL NEEDS IN THE MUNICIPALITY OF KUMANOVO	655
Bojan Jordanovski	655
Gordana Panova.....	655
REHABILITATION ACTIVITIES FOR CHILDREN WITH DYSLEXIA	661
Maria Becheva.....	661
Nina Becheva.....	661
Maria Bojkova	661
Zoia Koleva	661
Gergana Pavlova.....	661
Stilyana Bekir	661
AWARENESS OF TEACHERS IN EDUCATIONAL INSTITUTIONS ABOUT EPILEPSY	667
Dimitrina Blagoeva.....	667
INTELLECTUAL PROPERTY RIGHTS FOR BIOSIMILAR MEDICINAL PRODUCTS.....	673
Katerina Anchevska Netkovska.....	673
Aleksandra Grozdanova	673
HEALTH CARE MANAGEMENT AND ORGANIZATION PLANNING DURING COVID-19 – THE NEW CHALLENGE BEFORE HEALTH CARE MANAGERS	679
Magdalena Ninova.....	679
QUALITY COMMUNICATION AS A PREREQUISITE FOR QUALITY IMPROVEMENT AND SAFE IMPLEMENTATION OF HEALTH CARE	685
Vera Simic	685
Ivanka Adžić.....	685
Isidora Papic	685
Gordana Panova.....	685

EFFICIENT HOSPITAL MANAGEMENT BASED ON RISK ASSESMENT PRINCIPLES	693
Boyko Mirazchiyski	693
Lyubomir Bakalivanov	693
Elisaveta Petrova-Geretto	693
ADVANTAGES OF CREATING AND MAINTAINING A YOUTUBE CHANNEL FOR A DOCTOR OR DOCTOR’S PRACTICE.....	703
Victoria Jekova.....	703

THE ROLE OF DEHYDROEPIANDROSTERONE SULPHATE AND TESTOSTERONE IN ERECTILE DYSFUNCTION IN PATIENTS TREATED WITH 5 ALPHA REDUCTASE INHIBITORS

Maja Sofronievska Glavinov

University Surgical Clinic “ST.Naum Ohridski”, Skopje, Republic of North Macedonia

msofronievska@yahoo.com

Abstract: The pharmacological treatment of benign prostatic hyperplasia involves the use of mainly two groups of drugs: selective alpha 1 blocker and 5 alpha reductase inhibitors (5ARI). In patients who undergo 5ARI pharmacotreatment, adverse effects such as sexual disturbances such as erectile dysfunction and decreased libido may occur. The purpose of this study is to investigate the occurrence of these side effects, particularly erectile dysfunction in order to predict and overcome them more easily. We conducted a controlled prospective pharmaco-epidemiological study to evaluate the side effects with the use of 5ARI in 250 men with benign prostatic hyperplasia (BPH). Erectile function was assessed at the time of the initiation of therapy and at the time of active use of therapy in two consecutive periods of 6 months and 12 months. We evaluated two groups of patients: the control group of patients treated with alpha 1 blocker (tamsulosin), and the investigated group of patients treated with combination therapy of alpha 1 blocker (tamsulosin) and 5 alpha reductase inhibitors (dutasteride). The evaluation was conducted through questionnaires: IPSS (International Prostate Score System) to calculate the symptoms of benign prostatic hyperplasia (light, medium or severe) and IIEF-5 (International Index for Erectile Function-5) questionnaire for calculating erectile function. During the study measurement of serum levels of testosterone and dehydroepiandrosterone sulphate were performed respectively. Statistical results of nonparametric group analysis showed that erectile dysfunction appeared in 27 patients (22.5%) in the investigated group after 6- and 12-months therapy respectively which was statistically significant ($p < 0,05$). Twenty six of these patients (96,3%) have had lowered testosterone and dehydroepiandrosterone sulphate serum levels ($p < 0,05$). As a conclusion we recommend investigation of testosterone and DHEAS serum levels prior to starting therapy should be considered valuable in order to avoid 5ARI related erectile dysfunction.

Keywords: BPH, erectile function, testosterone, dehydroepiandrosterone-sulphate

1. INTRODUCTION

Medical treatment of BPH as golden standard involves the use of mainly two groups of drugs: selective alpha 1 blockers and 5 alpha reductase inhibitors (5ARI). While selective alpha 1 blocker inhibits smooth muscle contraction within prostate and lower urinary tract resulting in fast lower urinary tract symptoms (LUTS) relief, 5ARIs inhibit the conversion of testosterone (TST) to dihydrotestosterone (DHT), thus reducing prostate growth and enlargement. Therefore, 5ARIs affect the reduction of the prostate volume up to 20-30% after 6 to 12 months therapy (Oelke et al.,2015).

The most common side effects of 5ARI include sexual dysfunctions such as erectile dysfunction, decreased libido and ejaculatory disorders (Motofei et al.,2018). Literature data shows that after 2 years of 5ARI therapy, about 12% of patients must discontinue treatment with these drugs due to side effects, especially erectile dysfunction. Side effects induced with 5ARI therapy most often occur at the beginning of drug administration and are evidently reduced in intensity and frequency over time (Corona et al., 2017).

5ARIs not only block the conversion of testosterone (TST) to dihydrotestosterone (DHT), but they also directly reduce the activity of nitric oxide synthetase (NOA-S) in cavernous penile bodies, which compromises the erection in these individuals (Corona et al.,2020).

At the same time 5ARIs inhibit the bioconversion of other steroids in the body including neurosteroids that affects brain tissue activity; especially androstenedione conversion that has antiepileptic, antidepressive and anxiolytic function (Celec et al.,2015).

The only steroid that is not under 5 alfa reductase activity is dehydroepiandrosterone sulphate (DHEAS). It is a steroid precursor, excreted by zona reticularis of the adrenal gland. It also has been proven both as a direct stimulator to NOS activity in the endothelium and as neuromodulator in the brain. Genetic studies have shown that there is a precisely specific receptor (G-protein) on the plasma membrane to which DHEA binds. This DHEA receptor is functionally linked to all three subtypes of G-protein, which mediate the activation of nitric oxide synthetase (NOS). The released NO afterwards, causes a series of intracellular reactions, the goal of which is to decrease intracellular calcium which results in relaxation of the smooth muscle of the blood vessels and establishing erections of cavernous bodies (Zaric et al.,2020).

The aim of this study was to investigate the occurrence of erectile dysfunction as a side effect during 5ARI therapy in order to prevent and overcome its appearance.

2. MATERIAL AND METHODS

We conducted a prospective controlled clinical study to evaluate the side effects from the use of 5-alpha-reductase inhibitors (dutasteride) in men with benign prostatic hyperplasia (BPH). The research procedures were in line with ethical standards and the 1975 Helsinki Declaration, which was revised in Seoul in 2008. Each patient involved in this study agreed to participate and signed written consent. The study was approved by the ethical committee at the institution where it was conducted.

Two hundred and fifty patients aged 45 to 70 years with symptoms and signs for BPH that were referred to urologist for the first time were included in the study. The age framework was set widely in order to avoid age-related discrimination of sexually active male. The diagnosis of BPH was made by routine analysis of prostate volume with echotomography, prostate-specific antigen (PSA) determination, and lower urinary tract symptoms (LUTS) assessment with International Prostate Symptoms Score (IPSS) questionnaire. Inclusion criteria were prostate volume from 40 to 65 ml, PSA lower than 4ng/ml and IPSS between 12 and 26. Exclusive criteria were dementia, deafness, medical history for mental disorders, vascular disease and myocardial infarction, diabetes mellitus and prostatic cancer as well as the use of other medicines that may interfere with 5ARIs. All the patients included in the study were sexually active regardless of their marital status.

In this study we analyzed the control group of patients treated with tamsulosin as alpha 1 blocker (n=130/250) and the investigated group of patients treated with combination of tamsulosin and dutasteride (n=120/250).

International index for erectile function 5 questionnaire (IIEF-5) was used for the sexual function assessment. Patients fulfilled the questionnaire by their own as self-evaluation is considered to provide a more objective insight into the degree of symptoms, as the patient is not ashamed to give an objective answer when self-evaluating. The urologist afterwards interprets the final score of the questionnaire. During the study measurement of serum levels of testosterone and dehydroepiandrosterone sulphate were performed at the beginning of the study and after 6- and 12-months therapy, respectively.

3. RESULTS

The data obtained during the study were entered into the database and processed with the Statistica 7 program. The evaluation of the obtained data gave an insight into the impact of the BPH therapy on the sexual function. The basic values of the analyzed variables are presented in (Table 1).

Table 1. Basic values of the examined variables at the beginning of the study


Beginning point of study		n=250
volP	mean ± SD; min-max	50.93 ± 13.4; 30-89
	median (IQR)	50 (39 – 60)
PSA	mean ± SD; min-max; min-max	1.83± 1.1;0.07-4.09
	median (IQR)	1.6 (1.05 – 2.67)
TST	mean ± SD; min-max	390.19±142.6;114-776
	median (IQR)	379 (270 – 494)
TST <270 ng/dL	n(%)	65 (26)
DHEAS	mean ± SD; min-max	151.82 ± 67.2; 15-290
	median (IQR)	155 (96 – 208)
DHEAS <80 ug/dl	n(%)	45 (18)
IPSS	mean ± SD; min-max	17.08 ± 2.8;12-26
	median (IQR)	17 (15 – 19)
IIEF-5	mean ± SD; min-max	23.28 ± 1.1; 22-25
	(median (IQR)	23 (22 – 24)

The patients from the control and study group had nearly identical result in terms of the erectile function (p = 0.98). Nonparametric analysis of the erectile dysfunction regarding differences in the two groups after statistical assessment showed significant difference (p<0,05) as shown in table 2.

Table 2. Mann-Whitney analysis of patients according to qualitative analysis of erectile function through IIEF-5 score in both groups.

Group	IIEF -5		p value
	mean ± SD	median (IQR)	
0-month			
CG	23.28 ± 1.03	23 (22 – 24)	Z=0.03
IG	23.28 ± 1.06	23 (22 – 24)	p=0.98 ns
6th month			
CG	23.65 ± 0.99	24 (23 – 24)	Z=4.77
IG	20.14 ± 6.2	23 (21.5 – 24)	p=0.000002 sig
12th month			
CG	23.67 ± 1.1	24 (23 – 25)	Z=3.57
IG	20.28 ± 6.2	23 (20.5 – 24)	p=0.0004 sig


Figure 1. Graphic display of the IIEF-5 score in the control (CG) and test group (IG) at the beginning (a), after 6 months (b) and after 12 months (c).



As shown in table 2, the IIEF-5 in both groups of BPH patients before the start of therapy ranges from 22 to 25 i.e all the patients involved in the study had normal erectile function before therapy launching. After the introduction of therapy after 6 months (Figure 1b/M), erectile function improves in patients in the control group ($p < 0,05$). In the second group (IG), patients that were receiving combination therapy showed lowering of IIEF-5 score in 27 patients (22,5 %) (figure 1b/D). There was no improvement of erectile dysfunction in these 27 patients from the IG after 12 months of therapy (figure 2c/D).

Statistical analysis confirmed a significantly higher incidence of erectile dysfunction in IG at 6 ($p < 0.0001$) and 12 months from the start of treatment ($p < 0.0001$). In both control time points after 6 and 12 months of therapy, the difference between the two groups was significant in terms of the degree of erectile dysfunction ($p < 0.0001$) (figure 3).

Figure 3. Graphic representation of the percentage of patients with varying degrees of erectile dysfunction



Erectile dysfunction was most frequently represented in patients aged between 51 and 60 years (77,78%), in one patient aged under 51 years (3,7%) and in 5 (18,52%) patients aged between 61 and 70 years (table 3).

Table.3 Number of patients with ED regarding patients` age

Age (years)	Erectile dysfunction n (%)
45 – 50	1 (3.7)
51 – 60	21 (77.78)
61 – 70	5 (18.52)
(mean ± SD) (min – max)	(61.52 ± 5.2) (49 – 69)

DHEAS serum levels were measured in all patients in the same laboratory between 8 and 9 am at the beginning of therapy, and after 6 and 12 months, respectively.

Serum values of dehydroepiandrosterone sulfate at the start of therapy did not differ significantly between patients in the control and study groups ($p = 0.82$). The analysis did not find a statistically significant difference in the serum level of DHEAS between the two groups, after 6 months ($p = 0.87$) and 12 months after the start of therapy ($p = 0.79$)

Before the start of therapy and 6 months thereafter, 19 (14.6%) patients with CG and 26 (21.7%) within IG had decreased serum DHEAS values. At these two time points, a statistically significant difference was found between the two groups in terms of the prevalence of patients with normal and decreased serum DHEAS ($p = 0.15$). After 12 months of therapy, significantly lower serum DHEAS values were registered in patients with IG compared with CG ($p < 0.05$) (table 5).

Table 5. Pearson Chi-square analysis of patients in both groups according to the values of dehydroepiandrosterone sulfate in the three time points of the research

DHEAS ($\mu\text{g/dL}$)	GROUP			p value
	n	CG n (%)	IG n (%)	
0 month				
<80	45	19 (14.62)	26 (21.67)	$X^2=2.1$
>80	205	111 (85.38)	94 (78.33)	$p=0.15$ ns
6th month				
<80	45	19 (14.62)	26 (21.67)	$X^2=2.1$
>80	205	111 (85.38)	94 (78.33)	$p=0.15$ ns
12th month				
<80	42	16 (12.31)	26 (21.67)	$X^2=3.9$
>80	208	114 (87.69)	94 (78.33)	$p=0.048$ sig

The erectile dysfunction scale correlated positively significantly with serum DHEAS levels after 6 and 12 months of therapy, in both CG and IG ($p = 0.0002$). In the IG, a stronger correlation was registered, ($p < 0.0001$) in both control points (table 6).

Table 6. Spearman rank correlation between erectile function and DHEAS after 6 (a) and 12 (b) months

DHEA & IIEF-5	CG		IG	
	Spearman R	p-level	Spearman R	p-level
6 th month	0.321	0.0002	0.614	0.000
12 th month	0.269	0.002	0.650	0.000

During and after the treatment, no significant correlation was found in CG between the serum level of total testosterone and the score from the Index of Erectile Function ($p = 0.21$). In IG this analyzed correlation was significant both 6 months after the start of therapy and after the end of therapy ($p < 0.0001$) (table 7).

Table 7. Spearman rank correlation between erectile function and TST after 6 (a) and 12 (b) months

TST & IIEF	CG		IG	
	Spearman R	p-level	Spearman R	p-level
6 th month	0.111	0.21	0.521	0.000
12 th month	0.112	0.21	0.492	0.000

4. DISCUSSION

All patients participating in the study had normal sexual function before receiving BPH therapy and patients in the control and study groups had no significant differences in the IIEF-5 score ($p = 0.98$), but after 6 months of therapy in the study group patients treated with combination from tamsulosin and dutasteride a significantly lower IIEF-5 score was registered in 27 patients, ie the occurrence of erectile dysfunction in these 27 patients treated with combination therapy. Most of the literature data showed higher incidence of erectile dysfunction in patients treated with 5ARI versus placebo (Nickel et al.,1996, Skolarus et al., 2009, Edwards & Moore, 2002) or alpha blockers (Haque et al.,2018, López-Ramos et al., 2018).

The Korean study by Chi and Kim (2011) evaluates the effects of dutasteride were followed for one-year erectile function determined by the International Index of Erectile Function (IIEF-5) decreased significantly after 1 month and remained significantly reduced even after 12 months of treatment, as shown by the results in 27 men in this study. Methodologically, this study is close to the current research, in which the number of men with ED due to 5ARI therapy is 27 (22.5%).

In both groups, 75% of patients before and after BPH therapy had normal serum total testosterone levels. Decreased serum levels of total testosterone (<270 ng / dL) were reported in 34 (26.15%) CG patients and in 31 (25.8%) IG patients prior to therapy. In 26 patients from the IG who manifested erectile dysfunction after the treatment (96,3%), lowered levels of testosterone and DHEAS were obvious ($p < 0,05$). The presence of low DHEAS values (<80 mg/dL) in the control group without patients undergoing androgen blockade by dutasteride does not lead to obvious consequences regarding erectile function. In conditions when the androgenic function of testosterone is blocked, DHEAS as a primary steroid whose small but important role as a steroid is not subject to the action of 5ARI, assumes part of the role in the erection process. In these conditions erectile function is not disturbed.

Data from experimental and clinical studies show that DHEAS is a weak androgen that has no restorative effect on the erectile response but may contribute to the maintenance of erectile function in addition to the testosterone or dihydrotestosterone effect (Sahu et al.,2020).

DHEA has been shown to activate potassium channels by activating soluble guanylate cyclase and improving endothelial function by increasing nitric oxide (NO) synthesis and eventually dilating arteries and blocking vasoconstriction caused by hypoxia (Farukh et al, 1998).

Testosterone has an important and proven role in establishing the erection of the corpora cavernosa. Namely, its active isoform DHT stimulates the production of NO-synthetase in the corpora cavernosa, which enables the synthesis and release of NO in the endothelial cells of the blood vessels in the corpora cavernosa. The released NO causes a series of intracellular reactions, the goal of which is to reduce intracellular calcium as a result of which the smooth muscles of the blood vessels relax, dilate and establish an erection of the corpora cavernosa. Reducing the conversion of testosterone to dihydrotestosterone due to 5ARI inhibition reduces the amount of DHT that stimulates NO synthesis in the vascular endothelium of the corpora cavernosa. As a result, the amount of NO in the endothelial cells of the corpora cavernosa decreases, resulting in insufficient relaxation of the smooth muscle cells of the blood vessels in the corpora cavernosa and consequent insufficient erection of the same.

In conditions where DHT is reduced due to the blocked conversion of testosterone by 5ARI, the role of alternative stimulant of NO-synthetase is taken over by DHEA, which allows not to feel a drastic lack in stimulation of NO production in cavernous endothelial cells bodies. In cases where the amount of serum DHEAS is insufficient to cover the deficiency of DHT and as an alternative steroid to enable the release of NO in the corpora cavernosa, both the major and secondary biomechanisms of NO release are depleted. Due to this double lack of stimuli for NO

production, there is no relaxation of the smooth muscle cells of the blood vessels in the corpora cavernosa and as a result the erection process is unsatisfactory.

5. CONCLUSION

Summarizing the results of our study and data from the clinical studies it is clearly shown that in some patients, erectile dysfunction occurs after treatment with 5ARI. These side effects may not be significant in the comprehensiveness of the study, but for the individual patient this is a serious loss of quality of life and a serious individual approach should be taken before starting treatment with this type of drug.

Thus, investigation of testosterone and DHEAS serum levels prior to starting therapy should be considered valuable in order to avoid 5ARI related erectile dysfunction.

REFERENCES

- Celec P, Ostatnikova D, Hodosy J. (2015). On the effects of testosterone on brain behavioral functions. *Front Neurosci.*;9(12):1-17.
- Chi, BH.& Kim, SC. (2011). Changes in Sexual Function in Benign Prostatic Hyperplasia Patients Taking Dutasteride: 1-Year Follow-Up Results. *Korean J Urol*, 52, 632-636.
- Corona, G., Torres, L. O., & Maggi, M. (2020). Testosterone Therapy: What We Have Learned From Trials. *The journal of sexual medicine*, 17(3), 447–460. <https://doi.org/10.1016/j.jsxm.2019.11.270>
- Corona, G., Tirabassi, G., Santi, D., Maseroli, E., Gacci, M., Dicuio, M., Sforza, A., Mannucci, E., & Maggi, M. (2017). Sexual dysfunction in subjects treated with inhibitors of 5 α -reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. *Andrology*, 5(4), 671–678. <https://doi.org/10.1111/andr.12353>
- Edwards, J. E., & Moore, R. A. (2002). Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. *BMC urology*, 2, 14. <https://doi.org/10.1186/1471-2490-2-14>
- Farrukh, IS., Peng, W., Orlinska, U., Hoidal, JR. (1998). Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener. *Am J Physiol*, 274, 186-195.
- Haque, N., Masumori, N., Sakamoto, S., Ye, Z., Yoon, S. J., Kuo, H. C., Brotherton, B., Wilson, T., Muganurmath, C., McLaughlin, M., & Manyak, M. (2018). Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men. *International journal of urology: official journal of the Japanese Urological Association*, 25(11), 944–951. <https://doi.org/10.1111/iju.13785>
- López-Ramos H, Medina-Rico M, Bastidas D, et al. (2018). Pharmacologic treatment of benign prostatic hyperplasia: A literature review. *Rev Mex Urol.*;78(4):321-334
- Motofei, I. G., Rowland, D. L., Baconi, D. L., Tampa, M., Sârbu, M. I., Păunică, S., Constantin, V. D., Bălălău, C., Păunică, I., & Georgescu, S. R. (2018). Androgenetic alopecia; drug safety and therapeutic strategies. *Expert opinion on drug safety*, 17(4), 407–412. <https://doi.org/10.1080/14740338.2018.1430765>
- Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J. P., Afridi, S. K., & Elhilali, M. M. (1996). Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). *PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 155(9), 1251–1259.
- Oelke, M., Becher, K., Castro-Diaz, D., Chartier-Kastler, E., Kirby, M., Wagg, A., & Wehling, M. (2015). Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). *Age and ageing*, 44(5), 745–755. <https://doi.org/10.1093/ageing/afv077>
- Sahu, P., Gidwani, B., & Dhongade, H. J. (2020). Pharmacological activities of dehydroepiandrosterone: A review. *Steroids*, 153, 108507. <https://doi.org/10.1016/j.steroids.2019.108507>
- Skolarus, T. A., & Wei, J. T. (2009). Measurement of benign prostatic hyperplasia treatment effects on male sexual function. *International journal of impotence research*, 21(5), 267–274. <https://doi.org/10.1038/ijir.2009.26>
- Traish, AM., Hassani, J., Guay, AT., Zitzmann, M., Hansen, ML. (2011) Adverse side effects of 5 α -reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. *J Sex Med*, 8, 872-884.
- Zaric, M., Drakulic, D., Dragic, M., Gusevac Stojanovic, I., Mitrovic, N., Grkovic, I., & Martinovic, J. (2019). Molecular Alterations and Effects of Acute Dehydroepiandrosterone Treatment Following Brief Bilateral Common Carotid Artery Occlusion: Relevance to Transient Ischemic Attack. *Neuroscience*, 410, 128–139. <https://doi.org/10.1016/j.neuroscience.2019.05.006>